1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Hologic, Inc.
  6. Summary
    HOLX   US4364401012

HOLOGIC, INC.

(HOLX)
  Report
Real-time Estimate Cboe BZX  -  05/24 11:16:01 am EDT
78.35 USD   -0.59%
05/19INSIDER SELL : Hologic
MT
05/17SVB Securities Adjusts Hologic's Price Target to $85 from $82, Keeps Outperform Rating
MT
05/17Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
77.55(c) 78.12(c) 77.75(c) 78.81(c) 78.38 Last
2 246 467 2 117 538 1 729 502 1 565 491 314 092 Volume
-1.93% +0.74% -0.47% +1.36% -0.55% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4 671 M - -
Net income 2022 1 156 M - -
Net Debt 2022 294 M - -
P/E ratio 2022 17,3x
Yield 2022 -
Sales 2023 3 941 M - -
Net income 2023 694 M - -
Net cash position 2023 476 M - -
P/E ratio 2023 28,6x
Yield 2023 -
Capitalization 19 654 M 19 654 M -
EV / Sales 2022 4,27x
EV / Sales 2023 4,87x
Nbr of Employees 6 705
Free-Float 83,0%
More Financials
Company
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales (not including sold divisions) break down by area of application as follows: - molecular diagnostics (65.6%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral... 
Sector
Advanced Medical Equipment & Technology
Calendar
06/07 | 03:00pmPresentation
More about the company
Ratings of Hologic, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about HOLOGIC, INC.
05/19INSIDER SELL : Hologic
MT
05/17SVB Securities Adjusts Hologic's Price Target to $85 from $82, Keeps Outperform Rating
MT
05/17Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Hon..
BU
05/10Hologic Announces FDA Approval of Aptima® CMV Quant Assay for Human Cytomegalovirus
BU
05/10Hologic Announces FDA Approval of Aptima CMV Quant Assay for Human Cytomegalovirus
CI
05/10TRANSCRIPT : Hologic, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-..
CI
05/04Hologic to Webcast Presentation at Upcoming Investor Conference
BU
04/28Raymond James Trims Hologic's Price Target to $83 From $84, Maintains Outperform Rating
MT
04/27HOLOGIC : Announces Financial Results for Second Quarter of Fiscal 2022 - Form 8-K
PU
04/27TRANSCRIPT : Hologic, Inc., Q2 2022 Earnings Call, Apr 27, 2022
CI
04/27Hologic Earnings, Sales Decline in Fiscal Q2; Raises Fiscal 2022 Revenue, EPS Guidance
MT
04/27HOLOGIC INC Management's Discussion and Analysis of Financial Condition and Results of..
AQ
04/27HOLOGIC : Fiscal Q2 Earnings Snapshot
AQ
04/27Tranche Update on Hologic, Inc.'s Equity Buyback Plan announced on January 8, 2021.
CI
04/27Hologic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Marc..
CI
More news
News in other languages on HOLOGIC, INC.
05/10Hologic annonce l'approbation par la FDA du test Aptima CMV Quant pour le cytomégalovir..
04/27Baisse des bénéfices et des ventes de Hologic au deuxième trimestre de l'exercice fisca..
04/27Hologic, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 2..
04/27Earnings Flash (HOLX) HOLOGIC affiche un chiffre d'affaires de 1,44 milliard de dollars..
04/27Hologic, Inc. fournit des prévisions de bénéfices pour l'exercice 2022
More news
Analyst Recommendations on HOLOGIC, INC.
More recommendations
Stock Trading Strategies
HOLOGIC, INC. - 04/07
The calm spell can be taken advantage of to put on new positions
BUY
More Stock Trading Analysis
Chart HOLOGIC, INC.
Duration : Period :
Hologic, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HOLOGIC, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 78,81 $
Average target price 78,91 $
Spread / Average Target 0,13%
EPS Revisions
Managers and Directors
Stephen P. MacMillan Chairman, President & Chief Executive Officer
Karleen Marie Oberton Controller
Jay A. Stein Chairman, Chief Technical Officer & Senior VP
Sally W. Crawford Lead Independent Director
Christiana Stamoulis Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HOLOGIC, INC.2.94%19 654
THERMO FISHER SCIENTIFIC-16.80%217 320
DANAHER CORPORATION-23.07%180 262
INTUITIVE SURGICAL, INC.-38.32%78 637
SIEMENS HEALTHINEERS AG-16.86%64 649
EDWARDS LIFESCIENCES CORPORATION-25.80%58 644